Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

generalized pustular psoriasis - Clinical Profile, Treatments & Trials | Kisho | Kisho

Rare Disease

generalized pustular psoriasis

MONDO:0100491

Find Clinical TrialsTrials

Overview

A rare and extreme form of psoriasis characterized by the appearance of sterile pustules which can take many patterns. All the main pathological features of the disease are accentuated. Generalized pustular psoriasis is clinically heterogeneous in its age at onset, precipitants, severity, and natural history. Many overlapping clinical entities are recognized. There is a relationship between these entities and plaque psoriasis, as some individuals may have episodes of plaque psoriasis preceding or following the generalized pustular psoriasis, but in others generalized pustular psoriasis occurs as the sole phenotype without plaque psoriasis at any time.

Treatments1 FDA approved

Clinical Trials12 registered · 3 recruiting

Clinical Presentation

Built from Human Phenotype Ontology (HPO) phenotype annotations and GeneReviews clinical descriptions. Features represent findings documented across known cases — not an exhaustive list of possible symptoms.

Features include always present findings: Arthralgia, Elevated erythrocyte sedimentation rate, Erythematous plaque, and Pustule; and very common findings: Erythroderma, Abnormal nail morphology, and Pain. 27 total HPO annotations.

Organ System	Phenotype Count	Example Features
Skin	3	Erythematous plaque, Abnormal nail morphology, Palmoplantar pustulosis

Diagnosis

Biomarker and diagnostic research for generalized pustular psoriasis has been reported in the published literature.

Treatment

Compiled from FDA-approved drug records, orphan drug designations, and FDA Adverse Event Reporting System (FAERS) safety data. GeneReviews management guidance is included where available.

1 FDA-approved treatment is available for generalized pustular psoriasis, including SPESOLIMAB-SBZO (SPEVIGO, approved 2022). An additional 2 compounds hold orphan drug designation.

Approved Therapies

Brand Name	Generic Name	Mechanism	Approved	Market Status

Prognosis

Phenotype severity distribution: 4 always present features, 3 very common features, 8 common features.

Estimated prevalence: 1-9 in 1,000,000 (Rare).

Research Landscape

Sourced from ClinicalTrials.gov and PubMed. Publication types are classified using NLM-curated article metadata; research type breakdowns reflect the nature of published work for this disease.

12 clinical trials registered, 3 recruiting. Interventions under study include drug therapy, other interventions, and biologic therapy. Pipeline includes 1 PHASE4, 2 PHASE3, 4 PHASE2. Research is sponsored by a mix of industry and academic institutions.

NCT ID	Title	Phase	Sponsor	Status
[NCT06477536](https://clinicaltrials.gov/study/NCT06477536)

Data assembled from 6 of 12 sources · Last updated Sep 19, 2026, 5:30 AM UTC

MONDOHPOClinicalTrials.govFDAPubMedHGNCClinVarClinGenGeneReviewsOrphanetOMIMRUSP

Medical References

External Resources

Orphanet

European rare disease database

Orphanet:247353

Questions for Your Care Team

→What are the benefits and potential side effects of SPEVIGO for managing generalized pustular psoriasis?
→Are any of the 12 active clinical trials a good fit for my situation?
→Are there specialists or centers of excellence for this condition in my area?
→Is there a patient registry I should consider joining?

← Back to All Diseases

Brand Name	Generic Name	Sponsor	Designated	Exclusivity End	Designation Status
Recombinant Humanized Anti-interleukin 36R Monoclonal Antibody Injection (HB0034)	Recombinant Humanized Anti-interleukin 36R Monoclonal Antibody Injection (HB0034)	Shanghai Huaota Biopharmaceutical Co., Ltd.	2023	—	Designated
imsidolimab	imsidolimab	Vanda Pharmaceuticals Inc.	2020	—	Designated

Research Type	Count	% of Total
Patient case studies	47	21%
Research summaries	46	21%
Disease patterns and progression	41	18%
Clinical study results	32	14%
Other research	27	12%
Laboratory research	20	9%
New treatment approaches	7	3%
Testing and diagnosis research	4	2%

Kisho

generalized pustular psoriasis

Overview

Clinical Presentation

Diagnosis

Treatment

Approved Therapies

Prognosis

Research Landscape

Medical References

External Resources

Orphanet

Questions for Your Care Team

Questions for Your Care Team

Explore clinical features

Orphan Drug Designations

Clinical Trials

Recent Publications

Latest News & Developments

Efficacy and Safety of Recibokibart, an Interleukin-36 Receptor Antibody, in Generalized Pustular Psoriasis: A Phase 2 Randomized Trial.

Effectiveness and Safety of Spesolimab in Adolescents and Adults with Generalized Pustular Psoriasis.

Efficacy and safety of Janus kinase and TYK2 inhibitors in the treatment of generalized pustular psoriasis and palmoplantar pustulosis: a systematic review.

generalized pustular psoriasis

Overview

Clinical Presentation

Diagnosis

Treatment

Approved Therapies

Prognosis

Research Landscape

Medical References

External Resources

Orphanet

Related Diseases

Questions for Your Care Team

Questions for Your Care Team

Explore clinical features

Orphan Drug Designations

Clinical Trials

Recent Publications

Latest News & Developments

Efficacy and Safety of Recibokibart, an Interleukin-36 Receptor Antibody, in Generalized Pustular Psoriasis: A Phase 2 Randomized Trial.

Effectiveness and Safety of Spesolimab in Adolescents and Adults with Generalized Pustular Psoriasis.

Efficacy and safety of Janus kinase and TYK2 inhibitors in the treatment of generalized pustular psoriasis and palmoplantar pustulosis: a systematic review.